Archive: 2026/03
Lot-to-lot variability: Understanding natural variation in biologics and biosimilars
Lot-to-lot variability is a natural part of biologics and biosimilars, not a defect. Learn how the FDA ensures safety despite millions of tiny protein differences between batches, and why biosimilars aren't just generics.
read more